MAB13415
Anti-MMP-9 Antibody, clone GE-213
clone GE-213, Chemicon®, from mouse
Sinonimo/i:
Gelatinase B, 92 kDa Type IV Collagenase
Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
About This Item
Codice UNSPSC:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Prodotti consigliati
Origine biologica
mouse
Livello qualitativo
Forma dell’anticorpo
purified antibody
Tipo di anticorpo
primary antibodies
Clone
GE-213, monoclonal
Reattività contro le specie
human
Produttore/marchio commerciale
Chemicon®
tecniche
immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable
Isotipo
IgG1
N° accesso NCBI
N° accesso UniProt
Condizioni di spedizione
wet ice
modifica post-traduzionali bersaglio
unmodified
Informazioni sul gene
human ... MMP9(4318)
Specificità
Under non-reducing conditions, it recognizes proteins of 92 kDa and 86 kDa which are identified as pro (latent) and active forms of matrix metalloproteinase-9 (MMP-9; also known as 92 kDa and collagenase IV or gelatinase B) of human MMP-9. MAB13415 reacts with the complex (~200 kDa) of MMP-9 and tissue inhibitor of metalloproteinases-1 (TIMP-1; Nikkari et al., 1996). It shows no cross-reaction with pro and active forms of MMP-2 (Nikkari et al., 1996). Clone GE-213 also shows very low reactivity to mouse MMP-9 proteins by western blot, but at high enough antibody and antigen concentrations some detection is possible. Mouse immunhistochemistry is untested. Cellular Localization: Peripheral cytoplasmic.
Immunogeno
Purified human gelatinase B.
Applicazioni
Anti-MMP-9 Antibody, clone GE-213 is an antibody against MMP-9 for use in IP, WB & IH.
Research Category
Cell Structure
Cell Structure
Research Sub Category
MMPs & TIMPs
MMPs & TIMPs
Western Blotting (non-reducing; Nikkari et al., 1996) (Use Ab at 1μg/mL for 2hrs at RT)
Immunohistochemistry (Acetone-fixed frozen; Hurskainen, 1996): 1:100 for 30 minutes at room temperature
Immunoprecipitation: 2-5 μg/mg protein lysate (use protein G to precipitate immune complex).
Inhibition of MMP-9 Activity: 2-4μg/mL (Visscher, 1994)
Optimal working dilutions must be determined by end user.
Immunohistochemistry (Acetone-fixed frozen; Hurskainen, 1996): 1:100 for 30 minutes at room temperature
Immunoprecipitation: 2-5 μg/mg protein lysate (use protein G to precipitate immune complex).
Inhibition of MMP-9 Activity: 2-4μg/mL (Visscher, 1994)
Optimal working dilutions must be determined by end user.
Linkage
Replaces: 04-1150
Stato fisico
Format: Purified
Purified from ascites fluid by Protein G chromatography. Liquid in 10 mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide.
Stoccaggio e stabilità
Maintain at 2-8°C in undiluted aliquots for up to 12 months from date of receipt.
During shipment, small volumes of product will occasionally become entrapped in the seal of the product vial. For products with volumes of 200μL or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container′s cap.
During shipment, small volumes of product will occasionally become entrapped in the seal of the product vial. For products with volumes of 200μL or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container′s cap.
Risultati analitici
Control
POSITIVE CONTROL: Cytotrophoblastic columns, the endothelial and fibroblastic stromal cells of villi, and the large decidualized cells of decidual membrane in placenta (Hurskainen et al., 1996). Macrophages in arteries (Nikkari et al., 1996), and fibroblast, endothelial, and tumor cells in breast carcinomas (Soini et al., 1994; Visscher et al., 1994). Conditioned serum-free medium from (dexamethasone-treated) human fibrosarcoma HT-10801 (Nikkari et al., 1996) or endothelial HUVEC4 (Schnaper et al., 1993) cells.
POSITIVE CONTROL: Cytotrophoblastic columns, the endothelial and fibroblastic stromal cells of villi, and the large decidualized cells of decidual membrane in placenta (Hurskainen et al., 1996). Macrophages in arteries (Nikkari et al., 1996), and fibroblast, endothelial, and tumor cells in breast carcinomas (Soini et al., 1994; Visscher et al., 1994). Conditioned serum-free medium from (dexamethasone-treated) human fibrosarcoma HT-10801 (Nikkari et al., 1996) or endothelial HUVEC4 (Schnaper et al., 1993) cells.
Altre note
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Note legali
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Esclusione di responsabilità
Manufactured by Daiichi Fine Chemical Co., Ltd
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Non trovi il prodotto giusto?
Prova il nostro Motore di ricerca dei prodotti.
Codice della classe di stoccaggio
12 - Non Combustible Liquids
Classe di pericolosità dell'acqua (WGK)
WGK 2
Punto d’infiammabilità (°F)
Not applicable
Punto d’infiammabilità (°C)
Not applicable
Certificati d'analisi (COA)
Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
Zymographic analyses and measurement of matrix metalloproteinase-2 and -9 in nipple aspirate fluids.
Ferdinando Mannello et al.
Clinical chemistry, 49(9), 1546-1550 (2003-08-21)
Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound.
Marta Miguel Turu, Jerzy Krupinski, Esther Catena, Ana Rosell, Joan Montaner et al.
Atherosclerosis null
Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence.
Visscher, D W, et al.
International Journal of Cancer. Journal International Du Cancer, 59, 339-344 (1994)
Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species.
Roy, R; Louis, G; Loughlin, KR; Wiederschain, D; Kilroy, SM; Lamb, CC; Zurakowski, D; Moses, MA
Clinical cancer research : an official journal of the American Association for Cancer Research null
Jerzy Krupinski et al.
Vascular health and risk management, 3(4), 405-412 (2007-11-01)
Advanced atherogenesis is characterized by the presence of markers of enhanced prothrombotic capacity, attenuated fibrinolysis, and by clinical conditions associated with defective coagulation. Diabetes may be associated with enhanced lesion instability and atherosclerotic plaque rupture. Plaques obtained from 206 patients
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica.